S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Latest freight railroad layoffs and Wall Street pressure renew concerns about safety and service
Critical asset just had biggest fall on record (Ad)
One year after buying a failed bank, New York Community Bancorp is struggling
Dell, NetApp rise; Ginkgo Bioworks, New York Community Bancorp fall, Friday, 3/1/2024
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Friday, 3/1/2024
China pledges to increase opportunities for foreign companies as it seeks to boost its economy
Critical asset just had biggest fall on record (Ad)
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Latest freight railroad layoffs and Wall Street pressure renew concerns about safety and service
Critical asset just had biggest fall on record (Ad)
One year after buying a failed bank, New York Community Bancorp is struggling
Dell, NetApp rise; Ginkgo Bioworks, New York Community Bancorp fall, Friday, 3/1/2024
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Friday, 3/1/2024
China pledges to increase opportunities for foreign companies as it seeks to boost its economy
Critical asset just had biggest fall on record (Ad)
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Latest freight railroad layoffs and Wall Street pressure renew concerns about safety and service
Critical asset just had biggest fall on record (Ad)
One year after buying a failed bank, New York Community Bancorp is struggling
Dell, NetApp rise; Ginkgo Bioworks, New York Community Bancorp fall, Friday, 3/1/2024
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Friday, 3/1/2024
China pledges to increase opportunities for foreign companies as it seeks to boost its economy
Critical asset just had biggest fall on record (Ad)
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Latest freight railroad layoffs and Wall Street pressure renew concerns about safety and service
Critical asset just had biggest fall on record (Ad)
One year after buying a failed bank, New York Community Bancorp is struggling
Dell, NetApp rise; Ginkgo Bioworks, New York Community Bancorp fall, Friday, 3/1/2024
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Friday, 3/1/2024
China pledges to increase opportunities for foreign companies as it seeks to boost its economy
Critical asset just had biggest fall on record (Ad)
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches

BeyondSpring (BYSI) Competitors

$1.50
+0.17 (+12.78%)
(As of 03/1/2024 ET)

BYSI vs. CLRB, BOLT, LTRN, IPA, ELDN, DARE, NXTC, ACXP, CKPT, and TLSA

Should you be buying BeyondSpring stock or one of its competitors? The main competitors of BeyondSpring include Cellectar Biosciences (CLRB), Bolt Biotherapeutics (BOLT), Lantern Pharma (LTRN), ImmunoPrecise Antibodies (IPA), Eledon Pharmaceuticals (ELDN), Daré Bioscience (DARE), NextCure (NXTC), Acurx Pharmaceuticals (ACXP), Checkpoint Therapeutics (CKPT), and Tiziana Life Sciences (TLSA). These companies are all part of the "pharmaceutical preparations" industry.

BeyondSpring vs.

Cellectar Biosciences (NASDAQ:CLRB) and BeyondSpring (NASDAQ:BYSI) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership, valuation and community ranking.

Cellectar Biosciences presently has a consensus price target of $10.00, suggesting a potential upside of 138.10%. BeyondSpring has a consensus price target of $1.25, suggesting a potential downside of 16.67%. Given BeyondSpring's higher probable upside, research analysts plainly believe Cellectar Biosciences is more favorable than BeyondSpring.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cellectar Biosciences
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
BeyondSpring
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

Cellectar Biosciences has a beta of 0.94, suggesting that its stock price is 6% less volatile than the S&P 500. Comparatively, BeyondSpring has a beta of -0.13, suggesting that its stock price is 113% less volatile than the S&P 500.

Cellectar Biosciences received 52 more outperform votes than BeyondSpring when rated by MarketBeat users. However, 66.79% of users gave BeyondSpring an outperform vote while only 55.90% of users gave Cellectar Biosciences an outperform vote.

CompanyUnderperformOutperform
Cellectar BiosciencesOutperform Votes
237
55.90%
Underperform Votes
187
44.10%
BeyondSpringOutperform Votes
185
66.79%
Underperform Votes
92
33.21%

Cellectar Biosciences has higher earnings, but lower revenue than BeyondSpring.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cellectar BiosciencesN/AN/A-$28.60M-$3.25-1.29
BeyondSpring$1.35M43.24-$33.28MN/AN/A

Cellectar Biosciences' return on equity of 0.00% beat BeyondSpring's return on equity.

Company Net Margins Return on Equity Return on Assets
Cellectar BiosciencesN/A -3,821.29% -207.04%
BeyondSpring N/A N/A N/A

16.4% of Cellectar Biosciences shares are owned by institutional investors. Comparatively, 2.0% of BeyondSpring shares are owned by institutional investors. 4.6% of Cellectar Biosciences shares are owned by company insiders. Comparatively, 29.3% of BeyondSpring shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Cellectar Biosciences and Cellectar Biosciences both had 2 articles in the media. Cellectar Biosciences' average media sentiment score of 1.44 beat BeyondSpring's score of 0.44 indicating that BeyondSpring is being referred to more favorably in the news media.

Company Overall Sentiment
Cellectar Biosciences Neutral
BeyondSpring Positive

Summary

BeyondSpring beats Cellectar Biosciences on 6 of the 11 factors compared between the two stocks.


Get BeyondSpring News Delivered to You Automatically

Sign up to receive the latest news and ratings for BYSI and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BYSI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BYSI vs. The Competition

MetricBeyondSpringPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$58.38M$6.75B$5.00B$7.60B
Dividend YieldN/A2.82%2.88%3.87%
P/E RatioN/A14.53239.8417.54
Price / Sales43.24213.463,026.3273.87
Price / CashN/A19.1097.4954.95
Price / Book-4.174.894.584.71
Net Income-$33.28M$158.35M$114.57M$211.39M
7 Day Performance37.61%7.58%5.63%3.34%
1 Month Performance50.00%14.58%10.42%6.18%
1 Year Performance-19.35%8.37%13.75%9.60%

BeyondSpring Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CLRB
Cellectar Biosciences
0.4999 of 5 stars
$3.88
+11.2%
$10.00
+157.7%
+154.5%$47.69MN/A-1.1915Short Interest ↑
Gap Up
BOLT
Bolt Biotherapeutics
2.5318 of 5 stars
$1.20
-1.6%
$7.00
+483.3%
-26.7%$45.56M$5.73M-0.6394High Trading Volume
LTRN
Lantern Pharma
2.5418 of 5 stars
$4.50
+4.7%
$11.00
+144.4%
-22.7%$48.92MN/A-3.2122Insider Selling
High Trading Volume
IPA
ImmunoPrecise Antibodies
2.0099 of 5 stars
$1.86
flat
$8.00
+330.1%
-49.5%$48.96M$15.61M-3.96102Short Interest ↑
ELDN
Eledon Pharmaceuticals
3.4415 of 5 stars
$1.83
flat
$10.67
+482.9%
-30.0%$44.29MN/A-0.3317Short Interest ↓
News Coverage
Gap Up
DARE
Daré Bioscience
2.5441 of 5 stars
$0.50
+16.3%
$6.00
+1,098.8%
-48.6%$49.33M$10M-1.0625
NXTC
NextCure
4.3441 of 5 stars
$1.57
+4.0%
$5.50
+251.4%
+14.0%$43.66MN/A-0.6799Upcoming Earnings
Positive News
High Trading Volume
ACXP
Acurx Pharmaceuticals
3.3034 of 5 stars
$3.13
-3.7%
$14.00
+347.3%
-10.3%$43.10MN/A-2.984Analyst Report
Short Interest ↓
News Coverage
Gap Up
CKPT
Checkpoint Therapeutics
3.8771 of 5 stars
$2.14
+4.9%
$22.60
+956.1%
-54.7%$50.35M$190,000.000.0024Gap Up
TLSA
Tiziana Life Sciences
0 of 5 stars
$0.49
-2.0%
N/A-5.9%$50.61MN/A0.009Gap Down

Related Companies and Tools

This page (NASDAQ:BYSI) was last updated on 3/2/2024 by MarketBeat.com Staff